| Symbol | VRCDF |
|---|---|
| Name | VERICI DX PLC |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | CF64 2EZ United Kingdom Avon House 19 Stanwell Road |
| Telephone | +44 (0)20 7933 8780 |
| Fax | — |
| — | |
| Website | https://vericidx.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: LSE - London Stock Exchange |
| CIK | 0001831533 |
| Description | Verici Dx is a developer of advanced clinical diagnostics in organ transplant. Verici Dx kidney transplant assays are developed using next-generation sequencing science and leverages access to deep clinical insights derived from immunological, transcriptomic, clinical, and pathological data to define a personalized, precise risk-profile related to risk and diagnosis of kidney injury and graft loss for each patient over the course of their transplant journey. Additional info from OTC: |
No news found.